# EDGAR Filing Document

**Accession Number:** 0001372299
**File Stem:** 0001062993-23-000489
**Filing Date:** 2023-1
**Character Count:** 9484
**Document Hash:** 2a517c83361bb340c86a3f28237c2cea
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001062993-23-000489.hdr.sgml**: 20230105

**ACCESSION NUMBER**: 0001062993-23-000489

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20230101

**FILED AS OF DATE**: 20230105

**DATE AS OF CHANGE**: 20230105

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Upadhyay Arun
- **CENTRAL INDEX KEY:** 0001960039

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36751
- **FILM NUMBER:** 23511364

**MAIL ADDRESS:**
- **STREET 1:** C/O OCUGEN, INC.
- **STREET 2:** 11 GREAT VALLEY PARKWAY
- **CITY:** MALVERN
- **STATE:** PA
- **ZIP:** 19355
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Ocugen, Inc.
- **CENTRAL INDEX KEY:** 0001372299
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 11 GREAT VALLEY PARKWAY
- **CITY:** MALVERN
- **STATE:** PA
- **ZIP:** 19355
- **BUSINESS PHONE:** 484-328-4701

**MAIL ADDRESS:**
- **STREET 1:** 11 GREAT VALLEY PARKWAY
- **CITY:** MALVERN
- **STATE:** PA
- **ZIP:** 19355

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** HISTOGENICS CORP
- **DATE OF NAME CHANGE:** 20060810

## Exhibit 24.1

------

**Exhibit 24.1**

------

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Upadhyay Arun<br><sub>(Last) (First) (Middle)</sub><br>C/O OCUGEN, INC.<br>11 GREAT VALLEY PARKWAY<br><sub>(Street)</sub><br>MALVERN, PA 19355<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Ocugen, Inc. [ OCGN ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2023-01-01 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [ ] 10% Owner<br>[X] Officer (give title below)   [ ] Other (specify below)<br>_Chief Scientific Officer_ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Common Stock | 84159<sup>(1)</sup> | D |  |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Option (Right to Buy)<sup>(2)</sup> | <sup>(2)</sup> | 2027-02-07 | Common Stock | 1918 | $6.30 | D |  |
| Option (Right to Buy)<sup>(3)</sup> | <sup>(3)</sup> | 2027-12-15 | Common Stock | 1103 | $7.56 | D |  |
| Option (Right to Buy)<sup>(4)</sup> | <sup>(4)</sup> | 2028-08-31 | Common Stock | 2397 | $12.18 | D |  |
| Option (Right to Buy)<sup>(5)</sup> | <sup>(5)</sup> | 2028-12-19 | Common Stock | 4315 | $13.52 | D |  |
| Option (Right to Buy)<sup>(6)</sup> | <sup>(6)</sup> | 2029-04-08 | Common Stock | 479 | $12.41 | D |  |
| Option (Right to Buy)<sup>(7)</sup> | <sup>(7)</sup> | 2029-12-20 | Common Stock | 10000 | $0.405 | D |  |
| Option (Right to Buy)<sup>(8)</sup> | <sup>(8)</sup> | 2030-05-05 | Common Stock | 10000 | $0.34 | D |  |
| Option (Right to Buy)<sup>(9)</sup> | <sup>(9)</sup> | 2031-01-01 | Common Stock | 246000 | $1.83 | D |  |
| Option (Right to Buy)<sup>(10)(11)(12)</sup> | <sup>(10)(11)(12)</sup> | 2031-04-19 | Common Stock | 31120 | $5.64 | D |  |
| Option (Right to Buy)<sup>(13)</sup> | <sup>(13)</sup> | 2032-01-03 | Common Stock | 234993 | $4.72 | D |  |
| Option (Right to Buy)<sup>(14)</sup> | <sup>(14)</sup> | 2032-06-16 | Common Stock | 30000 | $1.95 | D |  |
| Option (Right to Buy)<sup>(15)</sup> | <sup>(15)</sup> | 2032-09-16 | Common Stock | 33818 | $2.17 | D |  |

---

### Footnotes:

(1) Consists of 84,159 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of common stock of Ocugen, Inc. (the "Company"). (i) 64,976 of the RSUs vest annually in equal installments over three years commencing on January 3, 2023, (ii) 10,000 of the RSUs vest annually in equal installments over three years commencing on June 16, 2023, and (iii) 9,183 of the RSUs vest annually in equal installments over three years commencing on September 16, 2023, in each case subject to continued service with the Company on the applicable vesting dates. The RSUs will be settled on each applicable vesting date in shares of the Company's common stock.

(2) The option vested annually in equal installments over three years commencing on February 7, 2018.

(3) The option vested annually in equal installments over three years commencing on December 15, 2018.

(4) The option vested annually in equal installments over three years commencing on August 31, 2019.

(5) The option vested annually in equal installments over three years commencing on December 19, 2019.

(6) The option vested annually in equal installments over three years commencing on April 8, 2020.

(7) The option vested annually in equal installments over three years commencing on December 20, 2020. The Reporting Person previously exercised 20,000 of the shares underlying the original option grant.

(8) The option vests annually in equal installments over three years commencing on May 5, 2021, subject to continued service with the Company on the applicable vesting dates. The Reporting Person previously exercised 20,000 of the shares underlying the original option grant.

(9) The option vests annually in equal installments over three years commencing on January 1, 2022, subject to continued service with the Company on the applicable vesting dates.

(10) On April 19, 2021, the Reporting Person was granted a performance-based option to purchase 77,800 shares of the Company's common stock based on the Company's satisfaction of five performance criteria prior to the end of the Company's 2021 and 2022 fiscal years, as applicable (the "Performance-Based Option"). With respect to each performance criteria, 10% of the Performance-Based Option vests on the date of the Compensation Committee's determination that the applicable criteria has been achieved (each, a "Determination Date") and an additional 10% vests upon the first anniversary of the applicable Determination Date, subject to the Reporting Person's continued employment with the Company on such date.

(11) On November 16, 2021, the Compensation Committee determined that one of the performance criteria had been achieved, resulting in the Performance-Based Option vesting in part as to 15,560 shares. 7,780 shares of the Performance-Based Option were immediately vested and exercisable, with the remaining 7,780 shares vested on November 16, 2022.

(12) On December 16, 2021, the Compensation Committee determined that the second performance criteria had been achieved, resulting in the Performance-Based Option vesting in part as to 15,560 shares. 7,780 shares of the Performance-Based Option were immediately vested and exercisable, with the remaining 7,780 shares vested on December 16, 2022.

(13) The option vests annually in equal installments over three years commencing on January 3, 2023, subject to continued service with the Company on the applicable vesting dates.

(14) The option vests annually in equal installments over three years commencing on June 16, 2023, subject to continued service with the Company on the applicable vesting dates.

(15) The option vests annually in equal installments over three years commencing on September 16, 2023, subject to continued service with the Company on the applicable vesting dates.

**Remarks:**
Exhibit List: Exhibit 24.1 - Power of Attorney

**Signature:** /s/ Arun Upadhyay by Jessica Crespo, his attorney-in-fact  
**Date:** 2023-01-05

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**